Mar 20, 2024
AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Mar 15, 2024
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

Mar 07, 2024
AIM ImmunoTech Announces Launch of CEO Corner Platform

Feb 29, 2024
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

Feb 14, 2024
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

Feb 08, 2024
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Jan 24, 2024
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

Jan 22, 2024
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca's Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

Jan 10, 2024
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Jan 05, 2024
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

 1     2    3   4   5   6   7